Contact Ching C. Lau, MD, PhD

Request An Appointment

Ching C. Lau, MD, PhD

Director, Center for Cancer and Blood Disorders
Martin J. Gavin Endowed Chair in Hematology/Oncology

Loading ratings
Practice Name Connecticut Children's Specialty Group

Meet Ching C. Lau, MD, PhD


BA, Rice University, 1977
PhD, Harvard University, 1982
MD, Harvard University, 1994

Baylor College of Medicine, 1993-1996

Cancer Genetics, Dana-Farber Cancer Center, 1982-1984
Pediatric Hematology & Oncology, Baylor College of Medicine, 1996-1998

Board Certifications

  • Pediatrics
  • Pediatric Hematology -Oncology
  • Faculty Appointment

    Professor of Pediatrics, University of Connecticut School of Medicine and Jackson Laboratory for Genomic Medicine

    Clinical Expertise

    Dr. Lau is Division Head of the Center for Cancer & Blood Disorders at Connecticut Children’s. His clinical interests include brain tumors, osteosarcoma, precision oncology, and genomics and genetics of cancer.

    Selected Publications

    • Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC. (2005) Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res, 65:8142-50.

    • Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, Hoang-Xuan K, Hallani SE, Idbaih A, Zelenika D, Anderson U, Henriksson R, Bergenheim AT, Feychting M, Lönn S, Ahlbom A, Schramm J, Linnebank M, Hemminki K, Kumar R, Hepworth SJ, Price A, Armstrong G, Liu Y, Gu X, Yu R, Lau CC, Schoemaker M, Muir K, Swerdlow A, Lathrop M, Bondy M, Houlston RS. (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nature Genet, 41:899-904.

    • Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, Il’yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, Yang P, Vick NA, Wrensch M, Davis FG, McCarthy BJ, Leung EH, Davis C, Cheng R, Hosking FJ, Armstrong GN, Liu Y, Yu RK, Henriksson R; Gliogene Consortium, Melin BS, Bondy ML. (2011) Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer Res, 71:7568-75. 2011.

    • Wang L, Yamaguchi S, Burstein MD, Terashima K, Chang K, Ng HK, Nakamura H, He Z, Doddapaneni H, Lewis L, Wang M, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adekunle A, Sun J, Qiao Y, Marth G, Muzny DM, Gibbs RA, Leal SM, Wheeler DA & Lau CC (2014). Novel somatic and germline mutations in intracranial germ cell tumors. Nature, 511(7508):241-5.

    • Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith M, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J. Mutational Landscape of the Genomes and Transcriptomes of 1,699 Pediatric Cancers, Nature 2018;555(7696):371-376. doi: 10.1038/nature25795.

    • View Dr. Lau’s full list of publications 

    Additional Information


    Ching C. Lau, M.D., Ph.D., since 2016 has served as JAX Professor, Division Head in UConn’s Department of Pediatrics’ Division of Pediatric Hematology/Oncology, and Martin J. Gavin Endowed Chair of Hematology-Oncology at Connecticut Children’s. He’s accelerating the pace and success rate of clinical trials in pediatric cancer patients using new genomic technologies to better understand pediatric brain and bone cancers and rapidly develop new therapeutic treatments for patients via translational research, especially difficult to treat brain tumors.

    By combining in silico drug screening and mouse model findings with genomic medicine to choose the best therapy for each patient, Lau hopes to improve the speed and outcome of clinical trials and reduce cancer care side effects for children. His latest research is gaining insight on the underlying genomics of common and difficult to treat brain tumor to target them genetically with novel therapeutics. Plus, he’s working to test and reposition current heart drugs to help expand the fight against complicated brain tumors.  More recently he is leading an international team of investigators in industry and academia to develop a cloud-based platform to facilitate data sharing and integration through global collaboration.

    Patient Feedback

    The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Patient Satisfaction Survey . Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments also are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.


    Recent Blog Posts by Ching C. Lau, MD, PhD

    Back to Top
    Searching Animation